Shilajit and Blood Pressure After Menopause: What the Studies Actually Show

Start with what the research cannot claim: shilajit is not a blood pressure medication. No clinical trial has tested it as a replacement for antihypertensive drugs, and framing it that way would misrepresent what the evidence actually shows.

What the research does show is something more specific and arguably more interesting. Multiple studies have found that shilajit supplementation improved the underlying vascular mechanisms that influence blood pressure in the first place: endothelial function, nitric oxide levels, and arterial stiffness. The distinction matters because those three factors are what blood pressure is a downstream symptom of, not the other way around.

What menopause does to vascular health

Women in their 20s and 30s tend to have better cardiovascular health profiles than men of the same age. That protection narrows and often reverses after menopause. The reason is estrogen.

Estrogen plays a central role in maintaining the health of blood vessels. It supports the production of nitric oxide, a molecule the endothelial cells lining your arteries use to signal the surrounding smooth muscle to relax. When the signal is working, arteries stay flexible and responsive to changes in blood flow. When the signal weakens, arteries become stiffer and the heart has to work harder to push blood through them.

After menopause, estrogen signaling drops and nitric oxide production tends to drop with it. This is why postmenopausal women experience significantly higher rates of arterial stiffness and elevated blood pressure than premenopausal women. The cardiovascular protection that came with their estrogen levels did not transfer forward.

Oxidative stress compounds the problem. Estrogen also acts as an antioxidant in the vascular endothelium, protecting the cells that line artery walls from damage. When estrogen signaling falls, oxidative damage accumulates in those cells. Damaged endothelial cells cannot produce nitric oxide efficiently. The stiffening and the blood pressure changes follow from there.

What the shilajit research measured

Three bodies of evidence point toward shilajit's effect on these specific vascular mechanisms.

The hypertension RCT. A randomized controlled trial published in the Indian Journal of Physiology and Pharmacology enrolled elderly adults with hypertension and tested purified shilajit against placebo. The researchers measured oxidative stress markers, arterial stiffness, and endothelial function directly. The treatment group showed significant reductions in oxidative stress and meaningful improvements in both endothelial function and arterial stiffness compared to the placebo group (https://ijpp.com/effect-of-purified-shilajit-asphaltum-punjabianum-on-oxidative-stress-arterial-stiffness-and-endothelial-function-in-elderly-with-hypertension-a-randomised-controlled-study/). These are the specific mechanisms upstream of blood pressure, not the blood pressure number itself.

Nitric oxide in the bone trial. The 48-week double-blind, placebo-controlled trial in postmenopausal women with osteopenia (Pingali et al., 2022, PMID 35933897) measured multiple biomarkers, including nitric oxide. The treatment group showed a rise in nitric oxide levels of approximately 50 to 60 percent compared to the placebo group. This finding came from a trial focused on bone density, which is why it is often overlooked in vascular discussions. But the vascular implication is direct: nitric oxide is the primary signal that maintains arterial flexibility. A 50 to 60 percent increase in that signal has clear relevance to the vascular consequences of menopause, even though blood pressure was not the primary endpoint.

Antioxidant protection. A 2018 review in the journal BioMed Research International examined the research on fulvic acid's mechanisms and found evidence for modulation of the immune response, reduction in TNF-alpha (a key driver of vascular inflammation), and improvement in oxidative stress markers (https://pmc.ncbi.nlm.nih.gov/articles/PMC6151376/). Oxidative stress in endothelial cells is one of the main reasons those cells cannot produce nitric oxide effectively. Reducing that burden directly supports the vascular environment.

Understanding the honest claim ceiling

It is worth being explicit about what this evidence does and does not support, because the blood pressure conversation in the supplement space is full of overclaimed findings.

Shilajit improved endothelial function and reduced arterial stiffness in a trial of elderly hypertensives. That is a real finding. It does not mean shilajit is interchangeable with antihypertensive medication, and nobody with a diagnosed blood pressure condition should adjust or discontinue medication based on supplement research.

What the evidence supports is a vascular health framing. The mechanisms that menopause disrupts, nitric oxide signaling, arterial flexibility, oxidative stress in endothelial cells, are mechanisms that the shilajit research has now tested and found improvements in. For postmenopausal women who are concerned about long-term vascular health, that is a meaningful signal.

The distinction between treating blood pressure and supporting vascular health is not a semantic one. Treating blood pressure means demonstrating a clinically significant drop in systolic or diastolic readings in a controlled trial designed for that outcome. Supporting vascular health means improving the conditions that allow arteries to function as they should. The shilajit research has done the second thing. No large trial has yet tried to do the first.

How fulvic acid addresses the estrogen-vascular connection

The mechanism linking shilajit to vascular health runs through the same pathway as several of the other post-menopause benefits: estrogen signaling.

Estrogen does not just influence bone and reproductive tissue. It has receptors throughout the cardiovascular system, including in endothelial cells. When the body's estrogen signaling weakens at menopause, all of those receptor sites become less active simultaneously. The bone changes, the vaginal tissue changes, and the vascular changes are all downstream of the same upstream event.

Shilajit is not a hormone. It does not replace estrogen. What the fulvic acid in it appears to do is support the body's own signaling pathway, nudging the system to respond more effectively to the hormonal signals that are still present. The 2022 Pingali trial in postmenopausal women is the strongest human evidence for this, both in study design (double-blind, placebo-controlled, 48 weeks) and in the range of biomarkers it measured.

When that signaling strengthens even modestly, the downstream effects include more active nitric oxide production and better endothelial cell function. The vascular improvements seen in the research may be following from the same root mechanism as the bone improvements in the Pingali trial.

For women with a family history of breast cancer

Shilajit is not a hormone and does not deliver estrogen to the body. The concern about estrogen and breast cancer applies to synthetic estrogen replacement, not to compounds that support natural signaling.

On the research side, a study published in Nutrients found that shilajit inhibited MCF-7 and MDA-MB-231 breast cancer cells and induced apoptosis while leaving normal breast cells unharmed (PMID 34466597). MCF-7 is the estrogen-receptor-positive breast cancer cell line used most commonly in research. The finding points in the opposite direction from what a synthetic estrogen product would show.

This is cell culture research, not a clinical trial. But it means the concern about estrogen-sensitive cancers does not transfer automatically to shilajit. The mechanisms involved are different.

Safety and what matters in a product

The shilajit research has consistently used purified preparations, and quality varies significantly among commercial products. Heavy metal content is the main concern. Shilajit forms inside rock and can carry geological contaminants if it is not properly processed. Independent third-party lab testing for heavy metals and mycotoxins, with results published as a certificate of analysis, is not optional. It is the baseline.

Fulvic acid concentration matters for the vascular mechanisms specifically. Most commercial products test at 15 to 20 percent fulvic acid. The clinical research used substantially higher concentrations. The certificate of analysis should show the fulvic acid percentage, not just claim one.

Zero serious adverse events have ever been reported across any human shilajit study.

What this means for you

The vascular effects of menopause are real, measurable, and well-documented. The estrogen decline at menopause sets in motion changes to nitric oxide production, endothelial function, and arterial stiffness that accumulate over years. The shilajit research has now tested these specific mechanisms in a hypertension trial and found meaningful improvements.

This does not make shilajit a blood pressure treatment. It makes it a researched approach to vascular health for postmenopausal women who want to support the underlying mechanisms that menopause disrupts.

Optimum Shilajit Trifecta combines purified shilajit from the Altai mountains with pearl powder and bamboo silica. It is independently third-party lab tested for heavy metals and mycotoxins, with lab results on the website. A family-owned company out of Florida. They do not sell on Amazon and do not wholesale.

References

1. "Effect of purified Shilajit (Asphaltum punjabianum) on oxidative stress, arterial stiffness and endothelial function in elderly with hypertension: a randomised controlled study." Indian Journal of Physiology and Pharmacology, 2023. https://ijpp.com/effect-of-purified-shilajit-asphaltum-punjabianum-on-oxidative-stress-arterial-stiffness-and-endothelial-function-in-elderly-with-hypertension-a-randomised-controlled-study/
2. Pingali U et al. "Efficacy and safety of purified Shilajit in postmenopausal women with osteopenia." Phytotherapy Research, 2022. PMID 35933897. https://pubmed.ncbi.nlm.nih.gov/35933897/
3. Winkler J, Ghosh S. "Therapeutic potential of fulvic acid in chronic inflammatory diseases and diabetes." Journal of Diabetes Research, 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6151376/
4. Rahmani Barouji S et al. Shilajit inhibition of MCF-7 and MDA-MB-231 breast cancer cells. Nutrients, 2020. PMID 34466597. https://pubmed.ncbi.nlm.nih.gov/34466597/